Sinha and colleagues explain the greater fragility to SARS-CoV-2 in cancer patients as a result of six main elements: older age, increased expression of the ACE2 receptor, increased expression of the TMPRSS2 protease, underlying immunosuppression (due to cancer and/or anti-cancer treatments), significant inflammatory response and cancer-induced pro-coagulant state13. This evidence concerns the gene TMPRSS2 and cancer.